We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intellia Therapeutics Inc | NASDAQ:NTLA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.2417 | 1.02% | 23.8417 | 23.24 | 23.87 | 24.32 | 23.51 | 23.76 | 1,495,262 | 23:30:02 |
From May 2019 to May 2024
Details of the upcoming presentations are as follows:
Wednesday, September 7th 2016 Wells Fargo Healthcare ConferenceLocation: The Westin Waterfront, BostonPresentation Time: 3:30-4:00 PM ET
Tuesday, September 13th2016 Morgan Stanley Global Healthcare ConferenceLocation: Grand Hyatt New York, New YorkPresentation Time: 5:15-5:40 PM ET
Wednesday, September 28thLeerink Rare Disease & IO Roundtable Series, 2016Location: Lotte New York Palace, New YorkPresentation Time: 2:05-2:30 PM ET
Individuals may access the presentations for each conference via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 224-804-4462 jenn.smoter@intelliatx.com Investor Contacts: John Graziano Trout Group +1 646-378-2942 jgraziano@troutgroup.com Chad Rubin Trout Group +1 646-378-2947 crubin@troutgroup.com
1 Year Intellia Therapeutics Chart |
1 Month Intellia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
